Diabetic Kidney Disease
Diabetes Kidney Disease is a major complication of diabetes and affects about one-third of all adult diabetics. It is the name by which kidney disorders in people with diabetes are defined when control of blood glucose and other associated factors has not been adequate.
- Diabetic nephropathy is completely asymptomatic until severe and often irreparable damage to kidney function occurs.
- Due to diabetic nephropathy, about 30% of dialysis is performed..
- Diabetic nephropathy is the leading cause of kidney transplantation in Western countries.
- 1 in 3 adults with newly diagnosed type 2 diabetes also have diabetic nephropathy, demonstrating that the disease began to develop as diabetes progressed.
- Early detection and treatment of diabetic nephropathy is essential to prevent further kidney damage.
Limitations of traditional Diabetes Kidney Disease
Tests in patients with type 2 diabetes consist of periodic blood and urine tests to detect inadequate early loss of protein in the urine (albuminuria) and impairment of kidney function. These tests are performed annually.
Nowadays the tests performed for the diagnosis of diabetic nephropathy are eGFR (Estimated Glomerular Filtration Rate Analysis) and ACR (Albumin to Creatine Ratio) to quantify how the kidneys work in relation to albumin or creatine.
These tests cannot predict the risk of developing kidney disease and can be very variable, producing different and inconclusive results.
No current test predicts the risk of diabetic kidney nephropathy.
The PromarkerD test is able to predict the incidence of diabetic nephrology with higher odds ratios than eGFR or ACR.
Predicts four-year risk of Diabetes Kidney Disease
- PromarkerD helps predict the risk of diabetes kidney disease before damage occurs.
- Predice una rápida reducción en la tasa de mortalidad por complicaciones de la diabetes tipo 2 en todas las definiciones clínicamente significativas de enfermedad renal diabética, independientemente de los factores de riesgo clínicos reconocidos.
- Combines three biomarkers and three clinical variables, and generates an estimated risk of developing the disease.
- Is the only independent predictor of diabetes kidney disease within four years, in patients with type 2 diabetes.
- Generates an estimate of low, moderate or high risk of developing the disease.
- Also diagnoses existing diabetes kidney disease that current test may miss.
Sensibility 86%, Specificity 78%, AUC 0.88
Prediction of incident diabetes kidney disease
- The PromarketD test predicted incident diabetes kidney disease with a higher adjusted odds ration compare to eGFR and ACR.
Clinical stydy data show the PromarkedD test is an independent predictor of rapid eGFR decline in type 2 diabetes across clinically significant definitions of diabetes kidney disease. The PromarkerD test uses two cut-offs to define low, moderate and high risk of developing diabetes kidney disease in the next four years.
How does PromarkerD work?
Data from clinical studies show that the PromarkerD test is an independent predictor of the rapid decline of eGFR in type 2 diabetes through clinically meaningful definitions of diabetic nephropathy.
- The PromarkerD test is ordered along with routine blood tests (eGFR and HDL cholesterol) for patients with diabetes.
- Patients’ blood is collected for analysis in a standard laboratory, and s is tested using the PromarkerD method.
- The test lab loads the results (PromarkerD biomarker panel, eGFR and HDL-Cholesterol) into the PromarkerD encrypted data cloud for processing.
- The PromarkerD Hub analyses the test results using Proteomics International’s proprietary algorithm.
- The PromarkerD Hub generates a Test Report with the patients predictive risk profile for diabetic kidney disease.
- The test lab sends the PromarkerD results report to physicians.
Are you a physician and want more information?